OUTCOMES REGISTER // COMPONENT RESULTS
KLOW Results in the Research Literature
The headline outcomes from each component's studies — what the investigators measured, in which species, at which dose, and what they found. The blend has no results of its own.
Reading the KLOW results board
KLOW results means component results. The blend has never been placed in a controlled experiment; it has no outcome table of its own. What this page documents are the headline findings from the four component arms — each clearly attributed to the component and the study that produced it. Nothing here is attributed to the KLOW combination without a combination study to support it.
TB-500 / thymosin beta-4 results
In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline. Wound contraction increased by at least 11% by day 7. Collagen deposition and angiogenesis were elevated. As little as 10 picograms of thymosin beta-4 stimulated keratinocyte migration two- to threefold in cell migration assays [1].
In male Wistar rats with embolic stroke, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg (starting 24 hours post-stroke, then every 3 days for 4 more doses) improved neurological function significantly from day 14 through day 56; 18 mg/kg showed no significant benefit (non-monotonic dose response) [10].
In a Phase 1 human study, full-length synthetic thymosin beta-4 IV up to 1260 mg was well tolerated in 40 healthy volunteers with no dose-limiting toxicities and dose-proportional pharmacokinetics [9]. These results are for the full 43-amino-acid protein; equivalence to the TB-500 heptapeptide fragment is not established.
BPC-157 results
BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical measures (load-to-failure, stiffness), functional recovery, collagen organization and macroscopic appearance; at 10 micrograms, 10 nanograms and 10 picograms per rat IP [2].
In a retrospective case series of 16 patients, intra-articular BPC-157 relieved multiple types of knee pain; 11 of 12 patients on BPC-157 alone and 3 of 4 on BPC-157 plus thymosin beta-4 reported significant improvement — 87.5% overall [11].
A 2025 IV safety pilot — 2 adults — found intravenous BPC-157 up to 20 mg well tolerated with no adverse events and no measurable biomarker changes [6]. A 2024 uncontrolled pilot in 12 patients with interstitial cystitis found complete symptom resolution in 10 of 12; all rated Global Response Assessment 5/5 [15]. A 2025 review states only three pilot studies have examined BPC-157 in humans and rates it investigational [14].
GHK-Cu results
GHK-Cu stimulated synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin in human skin studies. In topical placebo-controlled clinical trials, GHK-Cu formulations increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid. Documented clinical improvements in skin laxity, clarity, fine lines, wrinkle depth and density [4].
In a bioinformatic analysis of gene expression, GHK modulated the expression of approximately 31.2% of human genes at a 50%-or-greater change threshold — increasing 59% of affected genes and suppressing 41%, with strong stimulation of the ubiquitin-proteasome system, DNA-repair genes and antioxidant programs [5].
In rodent behavioral testing, GHK produced anxiolytic (anxiety-reducing) effects, reducing anxiety-like behavior in standardized assays [12]. Plasma GHK levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [4].
KPV results
In human intestinal epithelial cells (Caco2-BBE and HT29-Cl.19A lines) and Jurkat T cells, nanomolar KPV inhibited NF-kappaB nuclear import and MAPK activation, and reduced secretion of TNF-alpha, IL-6, IL-1beta and IL-8. In DSS- and TNBS-induced colitis in C57BL/6 mice, oral KPV at 100 micromolar in drinking water reduced colitis severity [3]. PepT1-mediated uptake was confirmed as the delivery mechanism — KPV enters inflamed gut cells through the same transporter that normally imports dietary di/tripeptides, at a Km of approximately 160 micromolar [3].
No controlled human efficacy trial of KPV as monotherapy has been published.
KLOW vs GLOW — what the components say
GLOW is a three-peptide blend (GHK-Cu, BPC-157, TB-500) that does not include KPV. KLOW adds KPV as the fourth arm — the NF-kappaB and MAPK inflammatory suppression channel that GLOW lacks. In research terms, the addition of KPV extends the blend's reach into the gut-mucosa and innate-immune suppression nodes that GHK-Cu, BPC-157 and TB-500 do not directly address in their primary study models.
No head-to-head study comparing KLOW to GLOW — in cells, rodents or humans — exists. The distinction between the two blends is structural and mechanistic, not empirical.
What no result covers
The KLOW results board has a deliberate gap: the combination itself. No outcome table for the four-peptide blend exists in the literature. The 'results' here are four separate data streams, not one convergent trial. A 2026 sports medicine review of unapproved peptide therapies concludes that animal-model promise does not automatically transfer to human benefit, and that scarce human safety data characterize this class of compound [7]. That review's conclusion is the accurate summary of the KLOW results record.